fr
en
Votre commande
Pharmacie Du Four Bonaparte
Pharmacie Du Four Bonaparte
There are no more items in your cart
Finalisez votre commande
0 items
€0.00
Total (tax incl.)
€0.00
Included taxes
€0.00
MYCOSTER Varnish 3ml
Pharmacotherapeutic class: Other topical antifungals.
MYCOSTER 8 PER CENT, film-forming solution for topical application in bottles is intended for the treatment of mycosis (onychomycosis) of the nails of the feet and hands. The active ingredient, ciclopirox, penetrates the nail and destroys the fungus.
You should contact your doctor if you do not feel any improvement or if you feel less well.
Prix : €7.66
Tax included
3400933418946
Data sheet
- Substances actives
- Ciclopirox
Specific References
Attention ceci est un médicament
Pour connaître les précautions d’emploi ainsi que la posologie, veuillez consulter la notice du médicament. Si vos symptômes persistent, consultez votre médecin.
This is a medicine.
In the interests of patients, the online sale of medicines is strictly regulated in France.
Our site is backed by the Citypharma French Pharmacy (Paris 6) and has been approved by the Île de France Regional Health Agency since July1, 2014.
Medicated varnish should be applied to the entire nail plate. Close the bottle tightly after each use.
Before starting treatment, we recommend removing any loose parts of diseased nails using nail clippers, a nail file or scissors.
Once a week, for the duration of the treatment, use a cosmetic dissolving solution to remove the film-forming layer on the surface of the nail, which could eventually hinder penetration of the active ingredient. At the same time, it is advisable to remove the free parts of the diseased nails.
Treatment should continue until clinical and mycological healing is complete, and healthy nails regrow.
Treatment usually lasts between 3 (finger onychomycosis) and 6 months (toe onychomycosis).
However, the duration of treatment should not exceed 6 months.
MYCOSTER is indicated for adults.
ANSM - Updated on : 05/02/2020
MYCOSTER 8 PER CENT, film-forming solution for topical application in bottle
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
Per 100 g film-forming solution
For full list of excipients, see section 6.1
.Film-forming solution for topical application.
Colorless, transparent solution.
4.2. Dosage and administration
Medicated varnish should be applied to the entire nail plate. Close the bottle tightly after each use
.Before starting treatment, we recommend removing any loose parts of diseased nails using nail clippers, a nail file or scissors
.Once a week, for the duration of the treatment, use a cosmetic dissolving solution to remove the film-forming layer on the surface of the nail, which could eventually hinder penetration of the active ingredient. At the same time, it is advisable to remove the free parts of the diseased nails
.Treatment should continue until clinical and mycological healing is complete, and healthy nails regrow
.Treatment usually lasts between 3 (finger onychomycosis) and 6 months (toe onychomycosis)
.
However, the duration of treatment should not exceed 6 months
.MYCOSTER is indicated for adults.
Hypersensitivity to ciclopirox or to any of the excipients listed in section 6.1.
In the absence of clinical data, MYCOSTER is not indicated for use in children.
4.4 Special warnings and precautions for use
Avoid contact with eyes or mucous membranes.
MYCOSTER nail polish is for external use
only.Do not apply ordinary nail polish or other cosmetic products to treated nails
. In the event ofsensitization, treatment should be discontinued and appropriate therapy
instituted.As with all topical treatments for onychomycosis, in the case of multiple nail involvement (>5 nails), where more than two-thirds of the nail plate is affected, and in the case of predisposing factors such as diabetes and immune disorders, the addition of systemic treatment should be considered
.In patients with a history of insulin-dependent diabetes or diabetic neuropathy, the risk of detachment of a detached or infected nail by the healthcare professional or during cleaning by the patient must be
taken into account.4.5. Interactions with other drugs and other forms of interaction
No interaction studies have been performed.
4.6. Fertility, pregnancy and lactation
Pregnancy
No embryotoxic or teratogenic effects have been observed after oral, topical or subcutaneous administration of ciclopiroxolamine in animals
.No effect of ciclopirox is expected during pregnancy due to negligible systemic exposure. Ciclopirox can be used during pregnancy.
Due tonegligible systemic exposure in nursing mothers, no effect on the infant is expected during lactation
.Ciclopirox may be used during lactation
.Fertility
No effect on male or female fertility has been demonstrated in experimental studies following oral administration of ciclopiroxolamine in rats
.4.7. Effects on ability to drive and use machines
Mycoster has no effect on the ability to drive vehicles and use machines.
Adverse events are classified below by organ system class and frequency. Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100, < 1/10), uncommon (≥ 1/1000, < 1/100), rare (≥ 1/10,000, < 1/1000) very rare (< 1/10,000), and undetermined frequency (cannot be estimated on the basis of available data)
.|
Organ system class and frequency (MedDRA classification) |
